Logo image of EIDX

Eidos Therapeutics Inc (EIDX) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:EIDX -

122.21
-6.23 (-4.85%)
Last: 1/25/2021, 8:00:44 PM
120.235
-1.97 (-1.62%)
After Hours: 1/25/2021, 8:00:44 PM

EIDX Key Statistics, Chart & Performance

Key Statistics
Market Cap4.75B
Revenue(TTM)127.00K
Net Income(TTM)-100.83M
Shares38.87M
Float7.51M
52 Week High132.54
52 Week Low28.39
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.65
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
EIDX short term performance overview.The bars show the price performance of EIDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150 200

EIDX long term performance overview.The bars show the price performance of EIDX in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of EIDX is 122.21 null. In the past month the price decreased by -4.04%. In the past year, price increased by 129.37%.

Eidos Therapeutics Inc / EIDX Daily stock chart

EIDX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to EIDX. When comparing the yearly performance of all stocks, EIDX is one of the better performing stocks in the market, outperforming 91.31% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EIDX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EIDX. While EIDX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EIDX Financial Highlights

Over the last trailing twelve months EIDX reported a non-GAAP Earnings per Share(EPS) of -2.6500000000000004. The EPS decreased by -231.25% compared to the year before.


Industry RankSector Rank
PM (TTM) -79392.91%
ROA -62.49%
ROE N/A
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%-538.89%
Sales Q2Q%-99.52%
EPS 1Y (TTM)-231.25%
Revenue 1Y (TTM)-99.52%

EIDX Forecast & Estimates


Analysts
Analysts55
Price TargetN/A
EPS Next Y-181.55%
Revenue Next YearN/A

EIDX Ownership

Ownership
Inst Owners0.01%
Ins Owners0.1%
Short Float %N/A
Short RatioN/A

About EIDX

Company Profile

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

Company Info

Eidos Therapeutics Inc

101 MONTGOMERY STREET SUITE 2550

SAN FRANCISCO CA 94104

CEO: Neil Kumar

Phone: 415-887-1471

Eidos Therapeutics Inc / EIDX FAQ

What does Eidos Therapeutics Inc do?

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.


What is the stock price of Eidos Therapeutics Inc today?

The current stock price of EIDX is 122.21 null. The price decreased by -4.85% in the last trading session.


What is the dividend status of Eidos Therapeutics Inc?

EIDX does not pay a dividend.


What is the ChartMill rating of Eidos Therapeutics Inc stock?

EIDX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of EIDX stock?

Eidos Therapeutics Inc (EIDX) has a market capitalization of 4.75B null. This makes EIDX a Mid Cap stock.


Who owns Eidos Therapeutics Inc?

You can find the ownership structure of Eidos Therapeutics Inc (EIDX) on the Ownership tab.